Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials.
From the aProgram in Medical Ethics, Center for AIDS Prevention Studies and Division of General Internal Medicine, USA
bGlobal Health Sciences, AIDS Research Institute and the Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA
cRopes and Gray LLP, and the Department of Internal Medicine, Yale Medical School, New Haven, Connecticut, USA.
Received 14 June, 2006
Revised 25 October, 2006
Accepted 10 November, 2006